Investigating new treatments for lung scarring in idiopathic pulmonary fibrosis
Screening of novel compounds through the reversal of gene expression in idiopathic pulmonary fibrosis
This study is looking for new ways to help people with idiopathic pulmonary fibrosis (IPF) by finding compounds that could change how certain genes work in the lungs, which might lead to better treatments for this tough lung disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry Ford Health + Michigan State University Health Sciences NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project ID | NIH-11040233 on NIH RePORTER |
What this research studies
This research focuses on understanding idiopathic pulmonary fibrosis (IPF), a serious lung condition characterized by scarring of lung tissue. The team aims to identify novel compounds that can reverse the gene expression changes associated with IPF, potentially leading to new therapies. By utilizing advanced techniques like single-cell RNA sequencing, they will analyze the small airways in the lungs to uncover the roles of different cell types in the disease. This approach may help in developing effective treatments that go beyond current options, which only slow disease progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with idiopathic pulmonary fibrosis who are seeking new treatment options.
Not a fit: Patients with other forms of lung disease or those who do not have idiopathic pulmonary fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to groundbreaking therapies that effectively reverse lung fibrosis and improve survival rates for patients with IPF.
How similar studies have performed: While there have been advancements in understanding IPF, this specific approach using novel compounds and single-cell analysis is relatively novel and has not been extensively tested.
Where this research is happening
East Lansing, United States
- Henry Ford Health + Michigan State University Health Sciences — East Lansing, United States (Active)
Researchers
- Principal investigator: Li, Xiaopeng — Henry Ford Health + Michigan State University Health Sciences
- Study coordinator: Li, Xiaopeng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.